The relentless pursuit of cutting-edge research and the development of new treatments for colorectal cancer is at the core of our endeavors at The Gloria Borges WunderGlo Foundation.
We are pleased to spotlight one of our Partner Advocates & Sponsors, Cardiff Oncology, who is on the frontline of developing a very promising new treatment option for KRAS Mutation Metastatic Colorectal Cancer.
Focused on addressing the once undruggable KRAS mutation, Cardiff Oncology is developing a new treatment option for patients in indications with the greatest medical need, including KRAS-mutated mCRC. Their goal is simple: to increase overall survival and duration of response.
In the world of drug discovery, “undruggable” targets are like the stubborn children of biology, proteins that are considered too challenging to bind with conventional molecules. Activated Ras is an extremely challenging direct drug target due to the inherent difficulties in disrupting the protein interactions that underlie its activation and function.
“Targeting the KRAS mutant colon cancers is a critical unmet need, and with onvansertib we have a promising novel agent which works synergistically
with irinotecan and bevacizumab in KRAS mutant colon cancer. ” – Dr. Heinz-Josef Lenz
WunderGlo’s Director & Wunder Project co-founder, Dr. Heinz-Josef Lenz is currently a lead investigator for the Phase 1b/2 clinical trial of Cardiff Oncology’s therapeutic candidate ovansertib in combination with standard-of-care, as a potential new second-line therapy for patients with KRAS-mutated mCRC.
The oral, highly selective PLK1 inhibitor is supported by compelling preliminary clinical data indicating improved treatment response and progression-free survival.
In fact, it is the only oral PLK1 inhibitor in clinical development that has demonstrated activity against KRAS-mutated mCRC.